In a deal worth up to $1.88 billion, Vir Biotechnology Inc. signed on to work with Gilead Sciences Inc. to discover and ...

Med-tech financings across all categories totaled $15.69 billion in the first nine months of 2026, down 33% from $23.34 ...

If you had told me when I graduated med school or left my residency that we would ever be able to treat pancreatic cancer ...

Since his May 2022 release from prison on a securities fraud conviction, Martin Shkreli has been violating a U.S. federal court order by publicly trading in biopharma stocks, engaging in public ...

Recognizing the unique challenges of developing and evaluating drugs to treat rare diseases, the U.S. FDA launched the Rare Disease Framework Initiative Oct. 14 to develop an optimized, ...

Roche AG an exclusive worldwide license for an RNAi candidate targeting activin receptor-like kinase 7 (ALK7). The compound deploys Shanghai-based Rona’s extrahepatic delivery platform and is designed ...

The Japanese government is seeking to strengthen the country’s global biotech position amid U.S. drug pricing changes and ...

The activin receptor-like kinase 7 (ALK7) pathway got another vote of confidence as Rona Therapeutics Inc. came to terms with ...

Sitryx Therapeutics Ltd. has delivered the first clinical data for a new mechanism of action (MOA) in atopic dermatitis and ...

Two phase III successes have delivered validation for Bristol Myers Squibb Co. across two strategically important programs, ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

U.S. President Donald Trump signed in the third quarter directly impact the biopharma and med-tech space, one of them has continued to court controversy as the Senate considers the nomination of Heidi ...